BioDelivery Sciences International Receives Buy Rating from Laidlaw (BDSI)
BioDelivery Sciences International (NASDAQ:BDSI)‘s stock had its “buy” rating restated by stock analysts at Laidlaw in a report issued on Monday. They currently have a $15.00 price objective on the stock. Laidlaw’s target price suggests a potential upside of 50.00% from the company’s current price.
BioDelivery Sciences International (NASDAQ:BDSI) traded down 0.90% on Monday, hitting $9.91. 2,047,424 shares of the company’s stock traded hands. BioDelivery Sciences International has a 52-week low of $3.86 and a 52-week high of $10.20. The stock’s 50-day moving average is $8.96 and its 200-day moving average is $7.63. The company’s market cap is $480.1 million.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Friday, May 9th. The company reported ($0.11) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. Analysts expect that BioDelivery Sciences International will post $-0.59 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at William Blair reiterated an “outperform” rating on shares of BioDelivery Sciences International in a research note on Monday. They now have a $23.00 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of BioDelivery Sciences International to $24.00 in a research note on Monday. Finally, analysts at TheStreet downgraded shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Friday, May 30th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $17.25.
BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.